Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025
CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on May 7, 2025 at 8:30 a.m. ET to discuss first quarter 2025 financial results and provide business updates.
To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4618787. To join the live webcast, please visit the 'Investors and News' section of the Seres website at www.serestherapeutics.com.
A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has received Breakthrough Therapy designation for the reduction of bloodstream infections in adults undergoing allo-HSCT and Fast Track designation for reducing the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT, and which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT. SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit www.serestherapeutics.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
30 minutes ago
- Globe and Mail
Advantages of Social Security Privatization, According to Experts
If you want to get people worked up, ask a small group of friends what they think of Social Security privatization. Privatization refers to the idea of shifting the management and funding of retirement from the government to individuals. In other words, rather than paying Social Security taxes as part of FICA, you would keep the money and invest for retirement on your own. Experts have dramatically different opinions on privatization, with some fearing that it will lead to more people entering retirement with little to no financial resources. Those arguing in favor of privatizing the program take a completely different view. Here's how they believe the change would benefit the average American worker. Higher returns Imagine that a portion of your Social Security taxes were invested in a personal account rather than used to fund current retirees' benefits. You could invest in stocks and bonds to your heart's content. In fact, you could invest in any vehicle you believe will provide a strong return. Compounding interest One of the beauties of investing is the way compound interest can significantly increase your retirement savings over time. As long as you begin investing early and are consistent, proponents of privatization believe you're in a position to build up more money than you could ever collect through Social Security payments. More flexibility Proponents believe that Americans will appreciate the ability to invest their retirement savings where they want. Rather than paying it into a program supporting current retirees, they can choose where their money will go. However, the open question becomes: What happens to the millions of current retirees when workers stop paying into the system? Focus on personal responsibility Read any message board, and you're likely to find plenty of people with an opinion about Social Security privatization. It's been a hot-button topic since President George W. Bush first suggested it in his 1978 Congressional race, then pushed for it again following his successful 2004 presidential campaign. Since that time, the subject has been supported by a rotating cast of politicians, who claim it will put the responsibility for saving on individuals rather than allowing them to depend on the government to provide a safety net. While this reasoning overlooks the fact that Americans spend decades contributing to the system and Social Security has never been a public assistance program, it does appeal to the "pull yourself up by your bootstraps" crowd. Greater financial literacy Proponents believe that pushing Americans to invest on their own means greater financial literacy among the masses. It's also believed that it will foster a culture of savings and investment. While this may be true for some, it's fair to imagine that wealthier Americans can afford to pay financial planners to help them make the most of their investments, while workers living paycheck to paycheck may have trouble saving the funds at all. It's likely that most people would like to save for retirement, but not everyone can afford to do so. The good news is that plenty of people are actively involved in seeking a solution to potential Social Security shortages. It may turn out that some form of Social Security privatization -- such as a hybrid system that allows you to continue paying into the current system while setting aside some money to make your own investments -- will be the answer. Or, it may be something entirely different. While proponents of Social Security privatization offer numerous potential advantages, it's yet to be seen if anyone will come up with a better solution. The $23,760 Social Security bonus most retirees completely overlook If you're like most Americans, you're a few years (or more) behind on your retirement savings. But a handful of little-known "Social Security secrets" could help ensure a boost in your retirement income. One easy trick could pay you as much as $23,760 more... each year! Once you learn how to maximize your Social Security benefits, we think you could retire confidently with the peace of mind we're all after. Join Stock Advisor to learn more about these strategies.
Globe and Mail
30 minutes ago
- Globe and Mail
Should You Buy Micron Stock Before June 25?
Micron (NASDAQ: MU) is scheduled to report quarterly financial results after the stock markets close on June 25, 2025. That has investors wondering if they should buy the semiconductor stock before the company announces its earnings results. *Stock prices used were the afternoon prices of June 18, 2025. The video was published on June 20, 2025. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Should you invest $1,000 in Micron Technology right now? Before you buy stock in Micron Technology, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Micron Technology wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor 's total average return is995% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. *Stock Advisor returns as of June 9, 2025 Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.
Globe and Mail
30 minutes ago
- Globe and Mail
Tesla Stock (TSLA) Buying Opportunity if Robotaxis are Another ‘Musk Mirage'
Tesla's (TSLA) much-anticipated robotaxi launch later this week is a 'pivotal' moment for the under-fire business, with any failure likely to severely hit its valuation and long-term revenue hopes. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Another 'Musk Mirage,' however, could create a buying opportunity for investors. Grand Illusion The warning from Saxo's global head of investment strategy Jacob Falkencrone comes ahead of Tesla's robotaxi launch on June 22 in Austin, Texas. 'It is a concept Elon Musk [Tesla chief executive] has relentlessly hyped as the cornerstone of Tesla's next trillion-dollar chapter,' he said. 'Investors now hold their breath. Will this launch deliver transformative change or prove yet another of Musk's grand illusions?' The robotaxi pilot will deploy roughly ten autonomous Model Y vehicles powered by Tesla's Full Self-Driving (FSD) software. Falkencrone said that while this is being marketed as fully autonomous, these robotaxis will initially operate within strict geo-fenced areas under remote human supervision—a controlled test environment 'reflecting cautious regulatory navigation rather than bold innovation.' Mobility Revolution Analysts estimate robotaxis could cut travel costs by up to 70%, revolutionizing urban transport and shifting Tesla from a carmaker to a global mobility giant. 'Robotaxis could redefine Tesla's revenue model, potentially surpassing its car business,' Falkencrone said. However, he said skepticism remains warranted given intense scrutiny from regulators and public safety advocates. Indeed, Democratic legislators in Texas recently publicly urged Tesla to postpone its rollout until new safety laws take effect on September 1. The National Highway Traffic Safety Administration (NHTSA) is also actively investigating Tesla's autonomous driving systems following multiple incidents. 'Historically, Tesla's stock follows a predictable pattern around product launches—rising sharply on anticipation and falling on reality,' Falkencrone said. 'The payoff potential is enormous, but so are the pitfalls. Positive early signs could signal a powerful, investable opportunity. Conversely, setbacks could create short-term buying opportunities amid volatility.' Is TSLA a Good Stock to Buy Now? On TipRanks, TSLA has a Hold consensus rating based on 14 Buy, 12 Hold and 9 Sell ratings. Its highest price target is $500. TSLA stock's consensus price target is $286.14 implying an 11.15% downside. See more TSLA analyst ratings
